Evaluation of Clopidogrel in Inhibition of Platelet Aggregation

Objective: Evaluation of In-vivo therapeutic effects of Clopidogrel 75mg (Lowplat) given once daily for seven days to the patients requiring antiplatelet therapy. Methodology: This is an open label, multicenter study to determine the platelet aggregation inhibition of the study drug in adult subjects suffering from diseases requiring antiplatelet therapy i.e. coronary artery diseases (CAD), peripheral vascular diseases (PVD) and cerebro vascular accident (CVA), presented at different hospitals and clinics in Faisalabad. Results: Mean platelet aggregation inhibited by (LP) was 66% (P <0.001) and standard deviation was ± 10%, which is statistically significant. Conclusion: This study proves that the Lowplat (LP) is effective in reducing platelet aggregation significantly in Pakistani patients’ who require antiplatelet therapy. The cost benefit of locally manufactured drug may be passed on to the patients.